XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 1.03%4.3B | 9.70%1.96B | 5.64%1.91B | -18.13%1.22B | 4.64%-781M | 22.89%4.26B | 18.71%1.78B | 30.87%1.81B | 15.76%1.48B | -16.67%-819M |
Net income from continuing operations | 8.29%4.12B | 4.71%801M | 1.90%752M | 8.88%1.14B | 13.74%1.42B | 23.16%3.8B | 62.42%765M | 33.70%738M | 7.06%1.05B | 15.29%1.25B |
Operating gains losses | -618.18%-57M | -3,800.00%-39M | 300.00%4M | 60.00%-2M | -205.26%-20M | 109.91%11M | 90.91%-1M | ---2M | 95.54%-5M | 58.33%19M |
Depreciation and amortization | 4.63%746M | 8.06%201M | 0.00%180M | -1.12%176M | 11.83%189M | -0.83%713M | -7.92%186M | 6.51%180M | 5.95%178M | -6.11%169M |
Other non cash items | -26.71%203M | -18.52%66M | 5.26%80M | -105.13%-2M | -27.16%59M | -33.25%277M | -57.81%81M | 22.58%76M | -47.30%39M | -6.90%81M |
Change In working capital | -18.39%-1.08B | 27.19%842M | 9.51%806M | -240.60%-187M | -3.98%-2.54B | 10.28%-908M | 17.38%662M | 44.03%736M | 56.47%133M | -12.29%-2.44B |
-Change in receivables | 0.00%-467M | 74.38%354M | 29.81%466M | -114.57%-545M | 4.26%-742M | 5.08%-467M | -19.76%203M | 54.08%359M | 53.73%-254M | -80.65%-775M |
-Change in payables and accrued expense | -52.82%92M | 3.22%674M | 0.16%644M | -2.81%553M | -6.53%-1.78B | 14.04%195M | 4.98%653M | 18.85%643M | 6.16%569M | -9.29%-1.67B |
-Change in other current assets | -40.91%-217M | -207.14%-172M | 70.00%17M | -85.45%8M | 57.06%-70M | -26.23%-154M | 48.15%-56M | -80.39%10M | 5.77%55M | -39.32%-163M |
-Change in other current liabilities | -0.79%-254M | 111.36%186M | -36.13%-260M | 44.12%-114M | -220.00%-66M | -93.85%-252M | 2.33%88M | -23.23%-191M | -464.29%-204M | 147.01%55M |
-Change in other working capital | 0.43%-229M | 11.50%-200M | 28.24%-61M | -169.70%-89M | 6.14%121M | 47.61%-230M | 21.80%-226M | 46.54%-85M | -230.00%-33M | 500.00%114M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 1.03%4.3B | 9.70%1.96B | 5.64%1.91B | -18.13%1.22B | 4.64%-781M | 22.89%4.26B | 18.71%1.78B | 30.87%1.81B | 15.76%1.48B | -16.67%-819M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -522.51%-8.82B | -1,512.87%-7.65B | 11.09%-393M | -212.03%-415M | 0.00%-368M | -66.71%-1.42B | 2.67%-474M | -320.95%-442M | -34.34%-133M | -131.45%-368M |
Capital expenditure reported | 24.04%-316M | 36.67%-76M | 34.23%-73M | 20.79%-80M | -3.57%-87M | 11.49%-416M | -16.50%-120M | 13.28%-111M | 13.68%-101M | 31.15%-84M |
Net business purchase and sale | -751.26%-8.45B | -2,011.52%-7.52B | 2.74%-319M | -1,215.38%-342M | 2.83%-275M | -119.21%-993M | 5.82%-356M | -455.93%-328M | -316.67%-26M | -910.71%-283M |
Net investment purchase and sale | -178.95%-53M | -842.86%-52M | 91.67%-1M | 160.00%6M | -50.00%-6M | -129.69%-19M | 800.00%7M | -115.79%-12M | -233.33%-10M | 50.00%-4M |
Net other investing changes | -90.91%1M | --0 | --0 | ---- | ---- | 22.22%11M | 0.00%-5M | 50.00%9M | -55.56%4M | 400.00%3M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -522.51%-8.82B | -1,512.87%-7.65B | 11.09%-393M | -212.03%-415M | 0.00%-368M | -66.71%-1.42B | 2.67%-474M | -320.95%-442M | -34.34%-133M | -131.45%-368M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 498.12%4.46B | 368.85%6.28B | -245.34%-1.44B | 4.95%-519M | -82.54%135M | -6.98%-1.12B | -117.32%-2.33B | 310.21%988M | -52.94%-546M | -9.59%773M |
Net issuance payments of debt | 244.35%6.55B | 2,914.90%7.18B | -170.44%-753M | 127.35%93M | -97.55%35M | 207.43%1.9B | -872.73%-255M | 405.43%1.07B | -395.65%-340M | 74.06%1.43B |
Net common stock issuance | 33.12%-636M | 409.86%220M | 3.47%-250M | -15.43%-419M | 27.52%-187M | 47.86%-951M | 40.34%-71M | 47.14%-259M | 40.98%-363M | 57.00%-258M |
Cash dividends paid | -16.56%-1.51B | -13.84%-403M | -14.45%-404M | -19.32%-352M | -19.59%-354M | -14.06%-1.3B | -18.79%-354M | -20.48%-353M | -7.27%-295M | -8.82%-296M |
Net other financing activities | 106.60%51M | 56.47%-720M | -105.46%-29M | -64.82%159M | 728.43%641M | -159.60%-773M | -139.71%-1.65B | -19.91%531M | 8.13%452M | -111.26%-102M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 498.12%4.46B | 368.85%6.28B | -245.34%-1.44B | 4.95%-519M | -82.54%135M | -6.98%-1.12B | -117.32%-2.33B | 310.21%988M | -52.94%-546M | -9.59%773M |
Net cash flow | ||||||||||
Beginning cash position | 16.94%14.15B | -6.84%13.72B | 3.26%13.15B | 9.04%12.91B | 16.94%14.15B | 6.40%12.1B | 29.09%14.73B | 11.33%12.74B | 5.40%11.84B | 6.39%12.1B |
Current changes in cash | -103.72%-64M | 157.17%586M | -96.48%83M | -65.09%281M | -144.93%-1.01B | 9.75%1.72B | -1,637.29%-1.03B | 191.58%2.36B | -2.54%805M | -6,800.00%-414M |
Effect of exchange rate changes | -226.22%-414M | -241.29%-633M | 234.81%488M | -145.56%-41M | -250.00%-228M | 139.00%328M | -40.35%448M | 56.75%-362M | 114.54%90M | 211.76%152M |
End cash Position | -3.38%13.67B | -3.38%13.67B | -6.84%13.72B | 3.26%13.15B | 9.04%12.91B | 16.94%14.15B | 16.94%14.15B | 29.09%14.73B | 11.33%12.74B | 5.40%11.84B |
Free cash flow | 3.75%3.99B | 13.05%1.88B | 8.24%1.84B | -17.93%1.14B | 3.88%-868M | 28.28%3.84B | 18.87%1.66B | 35.38%1.7B | 18.71%1.38B | -9.59%-903M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |